Evidence map›Paper›PMID 26168068›Full record

ArticleBone marrow transplantation2015

Favorable survival after allogeneic stem cell transplantation with reduced-intensity conditioning regimens for relapsed/refractory follicular lymphoma.

S Yano, T Mori, Y Kanda, J Kato, C Nakaseko, S Fujisawa, N Tomita, R Sakai, K Shono, T Saitoh and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 1 country.

S YanoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
T MoriDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Y KandaDivision of Hematology, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
J KatoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
C NakasekoDivision of Hematology, Department of Clinical Cell Biology, Chiba University Graduate School of Medicine, Chiba, Japan.
S FujisawaDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
N TomitaDepartment of Hematology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
R SakaiDepartment of Medical Oncology, Kanagawa Cancer Center, Yokohama, Japan.
K ShonoDepartment of Hematology, Chiba Aoba Municipal Hospital, Chiba, Japan.
T SaitohDepartment of Medicine and Clinical Science, Gunma University Graduate School of Medicine, Maebashi, Japan.
N AotsukaDepartment of Hematology, Narita Red Cross Hospital, Chiba, Japan.
N KobayashiLeukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.
T SaitoDivision of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan.
S TakahashiDivision of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
H KanamoriDepartment of Hematology, Kanagawa Cancer Center, Yokohama, Japan.
S OkamotoDivision of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.
Kanto Study Group for Cell Therapy (KSGCT)
Keio University · JPJikei University School of Medicine · JPChiba Aoba Municipal Hospital · JPChiba University · JPGunma Saiseikai Maebashi Hospital · JPGunma University · JPJapanese Red Cross Narita Hospital · JPJichi Medical University Saitama Medical Center · JPKanagawa Cancer CenterKanagawa Prefectural Hospital Organization · JPThe University of Tokyo · JPYokohama City University · JPYokohama City University Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allogeneic stem cell transplantation (allo-SCT) is a curative option for patients with relapsed follicular lymphoma (FL). Prospective studies of reduced-intensity conditioning (RIC) have revealed that chemosensitivity at allo-SCT is the most reliable predictor of outcome; however, limited data are available for progressive/refractory disease. We report here a retrospective analysis of RIC allo-SCT for patients with FL. The purpose of this study was to elucidate the role of allo-SCT for patients with relapsed/refractory FL. We analyzed 46 patients-11 (24%) transplanted in CR, 6 (13%) transplanted in PR and 29 (63%) with progressive/refractory disease. The estimated 5-year overall survival rate was 71.6% (95% confidence interval (CI), 51.5-84.5%). According to the disease status at transplantation, the 5-year survival rate was 80.7% (95% CI, 37.7-95.4%) in the patients with CR or PR and 66.1% (95% CI, 41.5-82.3%) in those with progressive/refractory disease (P=0.29). There were no differences in relapse/progression and non-relapse mortality between the patients with chemosensitive disease and progressive/refractory disease. Allo-SCT may be a valuable treatment option, even for patients with progressive/refractory FL.

Indexed as

AdultAgedFemaleHematopoietic Stem Cell TransplantationHumansLymphoma, FollicularMaleMiddle AgedRetrospective StudiesTransplantation ConditioningTransplantation, Homologous

Identifiers

PMID26168068
OpenAlexW1508153819

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.